# Jenny Yip

> Jenny Yip is a Series A investor at Antiva Biosciences backing Health Care. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: Antiva Biosciences
- Location: San Francisco, United States
- Total investments: 7
- Last investment: Apr 2023
- Lead investor: 57%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jenny-yip-08793126/

Jenny Yip is a Series A investor at Antiva Biosciences in San Francisco focused on Health Care and Biotechnology. Jenny is a Senior Program Investment Officer for the Program Related Investments (PRI) team at the Bill & Melinda Gates Foundation. She is responsible for leading and managing a wide range of investments in US education and sits on the boards of early stage start-ups and investment funds. Prior to joining the Foundation, Jenny was a VicePresident and Business Unit Manager at Goldman Sachs in the Investment Banking Division, responsible for leading financial advisory assignments for clients in the technology, media and telecom sectors in New York and San Francisco.Jenny has also worked at Yew Wah Education Management, a for-profit company operating K-12 schools across China, and volunteered at Technoserve in Nairobi, Kenya. During her time with Technoserve, she focused on cultivating a partnership with Millennium Villages Project for Enterprise Development in the Siaya District in Western Kenya and worked with Google.org looking at SME financing gaps in Kenya. Jenny graduated from Harvard University with an AB in History and Science and resides in San Francisco.

## Contacts

5 contacts available for Jenny Yip: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/jenny-yip?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 57% |
| Biotechnology | 4 | 57% |
| Medical | 2 | 29% |
| Women's | 1 | 14% |
| Genetics | 1 | 14% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 14% |
| Series B | 1 | 14% |
| Series C | 1 | 14% |
| Series D | 1 | 14% |
| Series E | 1 | 14% |

7 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Antiva Biosciences | Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco. | $53M | Series E | Apr 27, 2023 |  |
| 54gene | 54gene is a healthcare startup unlocking the African genome to fuel genetic research and development that may lead to new discoveries and benefit all populations.54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market: Nearly 90% of genetic material used in pharmaceutical research iscaucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions. | $50M | Convertible Note | Oct 28, 2022 |  |
| Antiva Biosciences | Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco. | $31M | Series D | Nov 02, 2021 |  |
| 54gene | 54gene is a healthcare startup unlocking the African genome to fuel genetic research and development that may lead to new discoveries and benefit all populations.54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market: Nearly 90% of genetic material used in pharmaceutical research iscaucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions. | $25M | Series B | Sep 16, 2021 |  |
| ChromaCode | ChromaCode is a molecular diagnostics company focusing on bioinformatics. It leverages patented mathematical methods and algorithmic enhancements to enrich signal processing from life science instrumentation. The company uses this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’sgold-standard biochemical assays at a very low cost.ChromaCode was founded in 2012, ChromaCode is headquartered in Carlsbad, California. | $10M | Series C | May 19, 2020 |  |
| 54gene | 54gene is a healthcare startup unlocking the African genome to fuel genetic research and development that may lead to new discoveries and benefit all populations.54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market: Nearly 90% of genetic material used in pharmaceutical research iscaucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions. | $15M | Series A | Apr 14, 2020 |  |
| Evofem Biosciences | Lithera is developing products for aesthetic medicine to address both medical and lifestyle indications. Its lead product is an injectable treatment to achieve local, selective fat tissue reduction (pharmaceutical lipoplasty). Using FDA registered drugs proven safe and effective in other indications, its product targets and stimulates natural fatmetabolism and achieves non-ablative, non-surgical fat tissue reduction in specific locations. | $25M | Post-IPO Debt |  |  |

7 of 7 investments shown.

## Co-investors
- [Ingressive Capital](https://shizune.co/investors/profile/ingressive-capital) — VC Fund, 4 deals together
- [Cathay Innovation](https://shizune.co/investors/profile/cathay-innovation-fund) — VC Fund, 3 deals together
- [KdT Ventures](https://shizune.co/investors/profile/kdt-ventures) — VC Fund, 3 deals together
- BioImpact Capital — VC Fund, 2 deals together
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund, 2 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 2 deals together

## About Antiva Biosciences

VC Fund · Del Mar, United States

Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

5 contacts available at Antiva Biosciences.

| Name | Title | Profile |
| --- | --- | --- |
| Jenny Yip | Director | — |
| Gail Maderis | President & CEO | — |
| Karl Hostetler | Founder & Consultant | — |
| Oranee Daniels | CMO | — |
| Sarah Walter | Vice President of Nonclinical Development | — |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jenny Yip invest in?

Jenny Yip invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Jenny Yip?

Public channels for Jenny Yip include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Jenny Yip last invest?

The most recent investment recorded for Jenny Yip closed in Apr 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co